This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Ruprecht-Karls-Universitat Heidelberg. Active years: 2018-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018-2022
Title: Zegeye Jebessa: Innovator in Cardiovascular Therapeutics
Introduction
Zegeye Jebessa is a prominent inventor based in Heidelberg, Germany. He has made significant contributions to the field of cardiovascular medicine through his innovative research and patented inventions. With a total of 2 patents, Jebessa is recognized for his work in developing therapeutic approaches for heart failure.
Latest Patents
Jebessa's latest patents focus on the use of Abhydrolase containing domain 5 (ABHD5) and N-terminal fragments of HDAC4 (HDAC4-NT) as therapeutic agents for the treatment and prevention of cardiovascular diseases. His inventions provide vectors for cardiomyocyte-specific expression of these peptides and a test system comprising ABHD5 for identifying novel compounds useful in treating heart failure. This groundbreaking work aims to improve treatment options for patients suffering from heart-related conditions.
Career Highlights
Throughout his career, Zegeye Jebessa has been associated with reputable institutions such as Ruprecht-Karls-University Heidelberg and Ruprecht-Karls-Universität Heidelberg. His academic and research endeavors have positioned him as a key figure in the field of cardiovascular research.
Collaborations
Jebessa has collaborated with notable colleagues, including Johannes Backs and Lorenz Lehmann. These partnerships have further enhanced his research capabilities and contributed to the advancement of cardiovascular therapeutics.
Conclusion
Zegeye Jebessa's innovative work in the field of cardiovascular medicine highlights his commitment to improving patient outcomes through research and invention. His contributions continue to pave the way for new therapeutic approaches in treating heart failure.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile